The week in pharma: action, reaction and insight – week to July 1 2022
By Barbara Obstoj-Cardwell. Editor
Last Monday, French drugmaker Ipsen said it has agreed to acquire US epigenetic therapies specialist Epizyme and its lead candidate Tazverik, for around $247 million. Blueprint Medicines entered a deal with Sixth Street and Royalty Pharma selling them royalties to Ayvakit and Gavreto for about $1.25 billion. Switzerland’s Roivant Sciences has set up another ‘vant’ – Priovant Therapeutics - with US pharma giant Pfizer taking a 25% stake, that will develop the autoimmune disease candidate brepocitinib. Also, Denmark’s Lundbeck and Japan’s Otsuka announced encouraging Phase III results of their brexpiprazole for the treatment of agitation in Alzheimer’s disease. Finally, the US Food and Drug Administration adapted new rules for COVID-19 booster jabs.
Epizyme accepts reality
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze